Background and Purpose-Atrial fibrillation (AF) is a common arrhythmic disorder among the elderly and sometimes progresses from paroxysmal to sustained (persistent or permanent) types. Clinical outcomes of patients with progression of AF were unknown. This study assessed the characteristics of patients with AF progression and the impact of AF progression on various clinical events. 
A trial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice and is associated with increased morbidity and mortality that primarily occur as a result of complications: thromboembolism and heart failure (HF). 1 In clinical practice, one should distinguish between the clinical types of AF, as follows: paroxysmal AF (PAF: episodes of arrhythmia that terminate spontaneously), persistent AF (episodes that continue for >7 days and are not self-terminating), and permanent AF (ongoing long-term episodes). 2 In the natural time course of AF, AF commonly progresses from silent and undiagnosed to PAF and subsequently sustained (persistent or permanent) AF (SAF). 3, 4 To determine the preferred treatment strategy in PAF, it is appropriate to consider risk factors for the progression of AF. In the CARAF study (Canadian Registry of Atrial Fibrillation), increasing age, significant aortic stenosis or mitral regurgitation, left atrial (LA) enlargement, and diagnosis of cardiomyopathy were independently associated with progression of AF. 5 More recently, the HATCH score (hypertension, age ≥75 years, transient ischemic attack or stroke, chronic obstructive pulmonary disease, and HF) 6 or the MB-LATER score (men,
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bundle branch block, LA ≥47 mm, type of AF, and early recurrent AF) 7 were proposed for predicting the progression of AF. It was reported that the MB-LATER score outperformed the HATCH score in regard to predicting the progression of AF. 8 However, risk stratification schemes of predicting the progression of AF have not been fully established in clinical practice.
Previously, we reported that SAF was independently associated with higher incidence of stroke or systemic embolism (SE) than PAF. 9 In a recent meta-analysis, SAF was associated with a highly significant increase in thromboembolism and death, when compared with PAF. 10 However, the prognosis and outcomes in patients with PAF before, during, and after the progression period remain unclear, especially among Asian patients with this common arrhythmia.
The aim of this present study was to assess the characteristics of patients with progression of AF and the impact of AF progression on the thromboembolism and various clinical events in a cohort of patients with AF enrolled in a specific region of Japan.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Patients
The detailed study design, patient enrollment, the definition of the measurements, and subjects' baseline clinical characteristics of the Fushimi AF Registry have been described previously. 11 The inclusion criterion for the registry is the documentation of AF on a 12-lead ECG or Holter monitoring at any time. A total of 80 institutions participated in the registry. The enrollment of patients was started in March 2011. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the ethical committees of the National Hospital Organization Kyoto Medical Center and Ijinkai Takeda General Hospital. Because the study belongs to the observational study, written informed consent was not obtained from patients according to the ethical guidelines for epidemiological research issued by the Ministry of Education, Culture, Sports, Science, and Technology and Ministry of Health, Labor, and Welfare, Japan.
Definitions
Type of AF was defined as the following in accordance with the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society and 2016 ESC guidelines for the management of patients with AF 2, 12 : PAF was defined as self-terminating AF, in most cases within 48 hours. Some AF paroxysms may continue for ≤7 days; persistent AF was defined as AF that lasts >7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after ≥7 days; and permanent AF was defined as AF that is accepted by the patient (and physician). SAF included both persistent AF and permanent AF.
We collected follow-up data of enrolled patients every year, and patients were classified into either type of AF by the decision of the attending physician at every data collection. Progression of AF was defined as changing type of AF from paroxysmal at baseline to sustained type (persistent or permanent) during follow-up period ( Figure 1 ). In patients with progression of AF, we divided the follow-up period into 3 distinct periods as follows: preprogression period was defined as the period before the time of last PAF; periprogression period was defined as the 1-year period changing from PAF to SAF; and postprogression period was defined as the period after the time of first SAF.
The primary end point in the analysis was the incidence of ischemic stroke (IS) or SE during follow-up period. Other clinical end points included the incidence of major bleeding, all-cause mortality, and hospitalization for HF during follow-up period. Stroke was defined as the sudden onset of a focal neurological deficit in a location consistent with the territory of a major cerebral artery, and the diagnosis of ischemic or hemorrhagic stroke was confirmed by computed tomography or magnetic resonance imaging. SE was defined as an acute vascular occlusion of an extremity or organ. Major bleeding was defined in accordance with the criteria of the International Society on Thrombosis and Haemostasis. Oral anticoagulants (OAC) included warfarin and non-vitamin K OACs, including dabigatran, rivaroxaban, apixaban, and edoxaban. Antiplatelet drugs included aspirin, clopidogrel, prasugrel, ticlopidine, and cilostazol. The values of LA diameter in echocardiography were collected at the time of enrollment.
We categorized the patients to stratify the risk of AF progression, using HATCH score (hypertension, age ≥75 years, transient ischemic attack or stroke [double], chronic obstructive pulmonary disease, and HF [double]), as originally described. 6 
Statistical Analysis
Continuous variables are expressed as mean and SD. Categorical variables are presented as numbers and percentages. We compared categorical variables using the χ 2 test and continuous variables using independent samples t test for normally distributed data or MannWhitney U test for non-normal distribution. The Kaplan-Meier method was used to estimate the cumulative incidences of AF progression. Univariate and multivariate logistic regression analyses were performed to identify the variables associated with progression of AF. Fine-Gray progression hazards model was used to estimate the association of AF progression with the clinical outcomes, considering the competing risk of mortality. We performed multivariate Cox proportional hazards model to determine the impact of AF progression on the incidence of clinical outcomes. The covariates chosen to be included were sex, age ≥75 years, history of stroke or transient ischemic attack, history of HF, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, chronic kidney disease, chronic obstructive pulmonary disease, history of major bleeding, prescription of OAC, prescription of β-blockers, and prescription of ACE (angiotensin-converting enzyme) inhibitor or ARB (angiotensin II receptor blocker) at baseline. Statistical significance was set at a 2-sided P value of <0.05. These analyses were performed using JMP, version 13.2.0 (SAS Institute, Cary, NC), and survival package for R, version 3.4.1, for Windows.
Results
Of 4441 patients who were enrolled 1 year before (by the end of November 2015), follow-up data (collected annually) were available for 4066 patients (follow-up rate, 91.6%) as of November 2016. Of these 4066 patients, 21 patients were excluded because their prescription data were unavailable at baseline. Finally, analyses were performed on 4045 patients (1974 patients with PAF and 2071 patients with SAF) at baseline ( Figure 1 ). During the median follow-up period of 1105 days (interquartile range, 669-1825 days), progression of AF occurred in 252 patients with PAF (4.22 per 100 person-years; Figure 2 ). On Kaplan-Meier analysis, the cumulative rate of progression to sustained type was 2.6% at 1 year, 11.4% at 3 years, and 28.3% at 5 years.
Characteristics of the patients at baseline, stratified by PAF with/without progression and SAF, are shown in Table 1 . PAF patients with progression were likely to have a longer mean interval since their first detection of AF and had larger mean LA diameter, compared with PAF patients without progression. PAF patients with progression were more frequent daily drinkers and more likely to have cardiomyopathy.
Baseline CHADS 2 , CHA 2 DS 2 -VASc, and HATCH scores were not significantly different between patients with PAF with and without progression. The numbers of patients with a CHA 2 DS 2 -VASc score of 0 were 9 (3.6%) in PAF patients with progression versus 91 (5.3%) in those without progression; 28 (11.1%) versus 215 (12.5%) for score of 1, and 215 (85.3%) versus 1416 (82.2%) for score of ≥2, respectively. The distributions of CHA 2 DS 2 -VASc score were statistically comparable between patients with PAF with and without progression (P=0.788). Compared with SAF patients, PAF patients with progression were significantly younger, with a shorter mean interval since first detection, less asymptomatic, and had smaller mean LA diameter. PAF patients with progression were less likely to have a history of stroke/transient ischemic attack, HF, and valvular heart disease. Baseline CHADS 2 , CHA 2 DS 2 -VASc, and HATCH scores were significantly lower in PAF with progression than SAF.
PAF patients with progression had higher baseline prescription of OAC than PAF without progression. Most medications and previous therapies were comparable between PAF with and without progression, except for lower frequency of catheter ablation in PAF patients with progression. Compared with SAF patients, PAF patients with progression were significantly less prescribed OAC and digitalis and more prescribed antiarrhythmic drugs.
Factors Associated With Progression to SAF
We performed logistic regression analysis to identify the variables associated with progression from PAF to SAF (Table 2) . On univariate analysis, body weight ≥60 kg, interval since first detection of AF ≥2 years, LA diameter ≥40 mm, daily drinker, cardiomyopathy, prescription of OAC, and catheter ablation were significant. On a multivariate model, which used factors of patients' characteristics that were significantly associated in our univariate model and previous studies (model 1), we indicated that interval since the first detection of AF, LA diameter, daily drinker, and cardiomyopathy were significantly associated with higher incidence of AF progression. On multivariate model 2, which included medications and interventions that might affect progression of AF in addition to model 1, catheter ablation was significantly associated with lower incidence of AF progression.
Outcomes
The incidences of clinical events are shown in Figure 3 . IS/ SE occurred in 3 patients during preprogression period, in 12 patients during periprogression period, and in 11 patients during postprogression period in PAF patients with progression. Hospitalization for HF occurred in 6 patients during preprogression period, in 19 patients during periprogression period, and in 12 patients during postprogression period. The incidence rates of clinical events were similar between PAF patients with progression during preprogression period and PAF patients without progression and between PAF patients with progression during postprogression period and patients with SAF. The incidence rates of IS/SE and hospitalization for HF during periprogression period were high.
Univariate Cox regression analysis of clinical events for AF progression is shown in Table I in the online-only Data Supplement. Unadjusted hazard ratios of IS/SE for PAF patients with progression during periprogression period were statistically significant, compared with PAF without progression and those with SAF. Using competing risk model to accommodate the competing risk of mortality, hazard ratios of IS/SE for PAF patients with progression during periprogression period were 3.79 (95% CI, 1.93-7.43; P<0.001), compared with PAF without progression, and 1.94 (95% CI, 1.05-3.61; P=0.036), compared with SAF. Also, 
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October 2018 Continuous variables are presented as mean and SD, and categorical variables are presented as numbers and percentages. AAD indicates antiarrhythmic drugs; ACE, angiotensin-converting enzyme; AF, atrial fibrillation; APD, antiplatelet drugs; ARB, angiotensin II receptor blocker; CHADS2, congestive heart failure (1 point), hypertension (1 point), age ≥75 years (1 point), diabetes mellitus (1 point), prior stroke or TIA or thromboembolism (2 points); CHA2DS2-VASc, congestive heart failure (1 point), hypertension (1 point), age ≥75 years (1 point), diabetes mellitus (1 point), prior stroke or TIA or thromboembolism (2 points), vascular disease (1 point), age 65-74 years (1 point), sex (1 point); HATCH, hypertension (1 point), age >75 years (1 point), stroke or transient ischemic attack (2 points), chronic obstructive pulmonary disease (1 point), and heart failure (2 points); LA, left atrium; NOAC, non-vitamin K oral anticoagulants; OAC, oral anticoagulants; PAF, paroxysmal atrial fibrillation; SAF, sustained atrial fibrillation; and TIA, transient ischemic attack. Comparisons between patients with and without IS/SE events during follow-up period are shown in the Table II in the online-only Data Supplement. Patients with IS/SE were older and had higher CHADS 2 and CHA 2 DS 2 -VASc scores than those without, among patients with PAF with and without progression, and patients with SAF. Prescription of OACs was not statistically different between patients with and without IS/SE. Furthermore, prescriptions of warfarin and non-vitamin K OACs were also similar, except that warfarin was more frequently given in those with IS/SE among patients with PAF without progression. In regard to hospitalization for HF, during preprogression period, unadjusted hazard ratio for PAF with progression was significant, compared with SAF.
On multivariate Cox regression analysis, progression of AF was significantly associated with an increased risk of IS/ SE during periprogression period and postprogression period, compared with PAF without progression ( Figure 4A ). Progression of AF was also significantly associated with a higher risk of hospitalization for HF during periprogression period. Multivariate Cox regression analysis indicated that progression of AF was associated with an increased risk of IS/ SE and hospitalization for HF during periprogression period, compared with SAF ( Figure 4B ).
Discussion
The principal findings of this study are as follows: (1) the incidence rate of AF progression was 4.2 per 100 person-years; (2) interval since the first detection of AF, LA diameter, daily drinker, and cardiomyopathy was significantly associated with an increased risk of progression of AF, and catheter ablation was significantly associated with lower incidence of AF progression; and (3) progression of AF was significantly associated with an increased risk of IS/SE and hospitalization for HF during periprogression period. The risk of adverse events was transiently elevated during periprogression 
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In the European Heart Survey, it was reported that progression of AF occurred in 15% patients at 1 year. The CARAF investigators demonstrated that the probability of progression by 1 year was 8.6%, and thereafter, there was a slow but steady progression to 24.7% by 5 years. In regard to Japanese patients with AF, Senoo et al 13 showed that the annual rate of AF progression was 6.0% per year. The prevalence of progression varies with patients' population, duration of AF at inclusion, and duration of follow-up. 14 Overall, the incidence rate of AF progression has been reported to be ≈5% per year, which was consistent with the present study.
Factors Associated With AF Progression
The present study indicated that interval since the first detection of AF, LA diameter, daily drinker, and cardiomyopathy was significantly associated with an increased risk of progression of AF. Factors included in the HATCH score were not independently associated with incidence of AF progression in our cohort. Many previous studies considered age as a risk factor for AF progression. 4, 5, [15] [16] [17] However, in our study, the interval since the first detection of AF was a risk factor for progression rather than age. Underlying cardiomyopathy and LA dilatation were well-recognized factors associated with progression of AF. 4, 5, 13, [18] [19] [20] In our study, daily drinking was an independent risk factor for AF progression. In the Framingham Study, the association between alcohol consumption and development of new-onset AF was indicated. 21 It was recently reported that alcohol consumption was a predictor of LA enlargement and subsequent incident AF. 22 Jongnarangsin et al 23 demonstrated that catheter ablation appeared to reduce the rate of AF progression, compared with a historical control group of pharmacologically treated patients with PAF. Consistent with this study, catheter ablation was associated with lower incidence of AF progression in the present study.
Clinical Events in Patients With Progression
Progression of AF was significantly associated with an increased risk of IS/SE and hospitalization for HF during periprogression period in our cohort. In the Belgrade Atrial Fibrillation Study, progression of AF was related to adverse events (including thromboembolism and congestive HF) in patients with newly diagnosed lone AF. 16 The clinical outcomes of patients who exhibit progression of AF were worse compared with patients demonstrating no AF progression with respect to hospital admissions and major cardiovascular events. 6 These previous studies demonstrated that adverse events occurred more frequently in patients with AF progression than those without progression but did not show when these events occurred: whether before, during, or after the AF progression.
In the present study, we demonstrated for the first time that the risk of adverse events temporarily increased during the periprogression period. Of note, risk factors for predicting thromboembolism, such as CHA 2 DS 2 -VASc score, were similar between PAF patients with progression and those without progression. Of note, AF progression is likely to be associated with progressive endocardial damage/dysfunction in the LA and hemodynamic instabililty because of frequent episodes of fibrillation and termination, which could lead to cardioembolic events. 24 In addition to the embolic events, AF may precipitate HF. 25 Consistent with a previous study, 26 progression of AF was significantly related to subsequent hospitalization for HF during progression period. Longer duration and more frequent episodes of AF may worsen cardiac function through rapid ventricular rates, a loss of atrial contraction, and an irregular ventricular filling time. Findings in this present study would provide clinical implication that practitioners would have an important indicator to better manage patient care, if duration or frequency of AF attacks would increase. 
Limitations
There were several limitations in this study. This is an observational study and provides only associative evidence, not causative. Data on exact burden, duration, and frequency of AF paroxysms are lacking. Because we do not have data on the date of AF progression, we do not know which comes first, AF progression or the occurrence of adverse events. The increased adverse events in patients who progressed to SAF may not have occurred as a result of the SAF and could be a consequence of progression of atrial fibrosis or other factors. Otherwise, the risks in PAF patients with progression to SAF may simply reflect the risks of the later. Medication and indication of catheter ablation were selected at the discretion of the attending physician and were not randomized. This present study was a nonrandomized study, thus the medications were confounded by indications. We also have no data on time in therapeutic range for individual patients taking warfarin. Finally, there was no adjudication committee for outcome events.
Conclusions
Progression of AF was associated with increased risk of clinical adverse events during arrhythmia progression period from PAF to SAF among Japanese patients with AF. The risk of adverse events was transiently elevated during progression period from PAF to SAF and declined to the level equivalent to SAF after the progression. SAF; B) . Hazard ratios were adjusted by sex, age ≥75 years, history of stroke/transient ischemic attack (TIA), history of heart failure, hypertension, diabetes mellitus, coronary artery disease, peripheral artery disease, chronic kidney disease, chronic obstructive pulmonary disease, history of major bleeding, prescription of oral anticoagulants, prescription of β-blockers, and prescription of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. HF indicates heart failure; NA, not applicable; and SE, systemic embolism.
